PeriVision is a technology company.
PeriVision has raised $3.0M across 1 funding round.
PeriVision has raised $3.0M in total across 1 funding round.
PeriVision has raised $3.0M in total across 1 funding round.
PeriVision's investors include DART Labs.
PeriVision is a Swiss medtech company that develops advanced eye testing solutions by integrating artificial intelligence (AI), virtual reality (VR), and cloud computing. Its flagship product, the VisionOne™ platform, offers a portable, fast, and accurate visual field test primarily aimed at diagnosing and monitoring glaucoma. PeriVision serves eye doctors, clinics, optometry practices, and biopharma partners by providing a more efficient, patient-friendly alternative to traditional bulky and time-consuming perimetry tests. The technology improves clinical workflow efficiency and delivers deeper insights into visual function, addressing a critical need as 2.2 billion people worldwide suffer from vision impairments, half of which could be prevented or cured with timely diagnosis[1][2][3][4].
Founded as a spin-off from the University of Bern, PeriVision’s origins trace back to 2017 with its first peer-reviewed publication on AI-based fast perimetry. The founding team includes CTO and co-founder Serife Seda Kucur (PhD in Biomedical Engineering), co-founder Raphael Sznitman, and CEO Patrick Kessel. Their combined expertise in biomedical engineering and AI led to the idea of modernizing perimetry testing, a gold standard in ophthalmology, by leveraging VR and AI to reduce test time and increase accessibility. Key milestones include clinical validations in 2018 and 2020, winning the EIT Health Wild Card accelerator in 2021, incorporation in 2022, and expansion to the US market in 2023. The VisionOne platform is now registered in major markets including the EU, US, and UK[1][2][3][4].
PeriVision rides the convergence of AI, VR, and cloud computing to transform ophthalmic diagnostics, a field traditionally reliant on bulky, stationary devices. The timing is critical due to the growing global burden of vision impairment driven by aging populations and lifestyle factors. Market forces favor solutions that increase efficiency, reduce costs, and enable remote or decentralized care. By enabling faster, more frequent, and more accessible eye testing, PeriVision contributes to a paradigm shift toward home-based chronic disease monitoring and personalized treatment decisions. Its technology also supports the broader digital health movement by integrating AI-driven insights into clinical workflows, influencing how eye diseases like glaucoma are managed worldwide[1][2][3][4].
Looking ahead, PeriVision is poised to expand its platform with new VR-based tests for additional retinal diseases and enhanced AI capabilities, aiming to deliver a comprehensive eye care solution. Trends such as telemedicine, AI-assisted diagnostics, and patient-centric care models will shape its growth trajectory. As the VisionOne platform gains wider adoption across the US, UK, and EU, PeriVision’s influence is likely to grow in redefining eye care standards and enabling earlier, more accurate diagnosis and monitoring. This evolution aligns with its mission to make eye testing accessible everywhere, potentially preventing vision loss for millions globally and transforming the future of ophthalmology[1][3][4].
PeriVision has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $3.0M Seed | DART Labs |